ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,277.51
      0.80%
      US Tech 100
      18,064.80
      0.02%
      Dow Jones
      38,686.32
      1.51%
      Brent Oil
      81.295
      0.00%
      Bitcoin
      67,721.69
      -0.01%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Affimed NV (AFMD)

      7. Affimed NV (AFMD) News

      AFMD

      Affimed NV (AFMD)

      Affimed NV
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:AFMD
      DateTimeSourceHeadlineSymbolCompany
      06/01/20241:02PMGlobeNewswire Inc.Affimed Provides Follow-up Data of AFM24 plus Atezolizumab Showing Durable Responses in Heavily Pretreated NSCLC EGFR Wild-type Patients and Positive Initial Data from the NSCLC EGFR Mutant CohortNASDAQ:AFMDAffimed NV
      05/29/20246:30AMGlobeNewswire Inc.Affimed Receives Fast Track Designation for Combination Therapy of AFM24 with Atezolizumab for EGFR Wild-Type Non-Small Cell Lung CancerNASDAQ:AFMDAffimed NV
      05/28/20246:51AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      05/28/20246:30AMGlobeNewswire Inc.Affimed Announces Annual General Meeting of ShareholdersNASDAQ:AFMDAffimed NV
      05/23/20245:22PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      05/23/20245:05PMGlobeNewswire Inc.Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024NASDAQ:AFMDAffimed NV
      05/14/202410:05AMGlobeNewswire Inc.Affimed Announces Acceptance of an Abstract on Preclinical Data of its Innate Cell Engager AFM28 at the European Hematology Association 2024 CongressNASDAQ:AFMDAffimed NV
      04/24/20244:05AMGlobeNewswire Inc.Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical OncologyNASDAQ:AFMDAffimed NV
      03/28/20246:30AMGlobeNewswire Inc.Affimed Reports 2023 Financial Results and Operational ProgressNASDAQ:AFMDAffimed NV
      03/21/20246:30AMGlobeNewswire Inc.Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024NASDAQ:AFMDAffimed NV
      03/11/20244:05PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      03/06/20246:34AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      03/06/20246:30AMGlobeNewswire Inc.Affimed Announces 1-for-10 Reverse Stock SplitNASDAQ:AFMDAffimed NV
      01/08/20244:45PMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      01/08/20244:05PMGlobeNewswire Inc.Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerNASDAQ:AFMDAffimed NV
      01/08/20248:11AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      01/08/20248:00AMGlobeNewswire Inc.Affimed Announces Leadership Change and Organizational RestructuringNASDAQ:AFMDAffimed NV
      01/03/20246:30AMGlobeNewswire Inc.Affimed Announces Sale of Wholly-Owned Subsidiary AbCheckNASDAQ:AFMDAffimed NV
      12/11/20236:10AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      12/11/20236:02AMGlobeNewswire Inc.Affimed Announces Positive Data for AFM24 in Combination with the PD-L1 Checkpoint Inhibitor Atezolizumab in Heavily Pre-treated EGFR-Wildtype Non-Small Cell Lung Cancer PatientsNASDAQ:AFMDAffimed NV
      12/11/20236:00AMGlobeNewswire Inc.Affimed Announces Updated Phase 1/2 Data from Acimtamig in Combination with Allogeneic NK in Hodgkin Lymphoma Patients Who Failed Prior Chemotherapy and Are Double-Refractory to Brentuximab Vedotin (BV) and Checkpoint Inhibitors (CPIs)NASDAQ:AFMDAffimed NV
      12/04/20236:30AMGlobeNewswire Inc.Affimed to Host Investor Conference Call Highlighting Clinical Data for Acimtamig (AFM13) and AFM24NASDAQ:AFMDAffimed NV
      11/30/20237:00AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
      11/14/20236:30AMGlobeNewswire Inc.Affimed Reports Third Quarter 2023 Financial Results and Highlights Operational ProgressNASDAQ:AFMDAffimed NV
      11/09/20236:30AMGlobeNewswire Inc.Affimed Announces Acimtamig as International Nonproprietary Name for AFM13NASDAQ:AFMDAffimed NV
      11/07/20236:30AMGlobeNewswire Inc.Affimed to Report Third Quarter 2023 Financial Results & Corporate Update on November 14, 2023NASDAQ:AFMDAffimed NV
      11/03/202312:05PMGlobeNewswire Inc.Affimed Presents Preclinical Data Showing that Addition of an Innate Cell Engager to NK and CAR-NK Cells Improves Tumor Cytotoxicity of Both Cell Types at the 38th Annual Meeting of the Society for Immunotherapy of CancerNASDAQ:AFMDAffimed NV
      11/02/20239:05AMGlobeNewswire Inc.Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual MeetingNASDAQ:AFMDAffimed NV
      11/01/20236:30AMGlobeNewswire Inc.Affimed to Participate in Upcoming Investor ConferencesNASDAQ:AFMDAffimed NV
      10/04/20236:40AMEdgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:AFMDAffimed NV
       Showing the most relevant articles for your search:NASDAQ:AFMD